Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2019; 19(1):41-46,62
DOI: 10.5428/pcar20190111
Meta analysis of the efficacy and safety of apatinib in treatment of patients with advanced gastric cancer
1. LI Chunxing(Department of Pharmacy,Aerospace Center Hospital,Beijing 100049,China 2008yuejuan@163.com)
2. LIU Hua(Department of Pharmacy,Aerospace Center Hospital,Beijing 100049,China zflhzflh@sina.com)
3. YOU Kai(Department of Pharmacy,Aerospace Center Hospital,Beijing 100049,China )
ABSTRACT  Objective: To systematically evaluate the efficacy and safety of apatinib in treatment of patients with advanced gastric cancer(AGC),so as to provide evidence-based reference for clinical medication.Methods: The pertinent randomized controlled trials(RCT) about apatinib and conventional therapy in the treatment of AGC were retrieved from Cochrane library,PubMed,Chinese National Knowledge Infrastructure(CNKI) and Wanfang Data Digitalization Database.The quality of the included studies were evaluated according to modified Jadad scale.Then,the related data was extracted and meta analysis was performed by using RevMan 5.3 statistical software.Results: A total of 20 RCT were included,involving 1379 patients.The results of meta analysis showed that objective response rate(ORR),disease control rate(DCR) and overall survival(OS) were significantly increased,the progression free survival(PFS) was ramarkably prolonged and patients’ quality of life was significantly improved in the apatinib treatment group,as compared with the control group (P<0.01,P<0.001).Rates of adverse drug reactions (ADRs) of hypertension and proteinuria increased with statistical significance in the apatinib treatment group,as compared with those in the control group.The rates of other ADRs was not statistically significant.Conclusion: Apatinib showed good therapeutic efficacy in the first or second or above-line treatment of AGC and could effectively improve ORR,DCR,OS,patient life quality,and prolong PSF.However,one should be highly aware of such ADRs as hypertension and proteinuria.In consideration of low quality of some included randomized controlled trials,more high-quality and large-sample randomized controlled trials are expected to support this conclusion.
Welcome to PCAR! You are the number 262 reader of this article!
Please cite this article as:
LI Chunxing,LIU Hua,YOU Kai,. Meta analysis of the efficacy and safety of apatinib in treatment of patients with advanced gastric cancer[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(1): 41-46,62.
References:
1. ZUO Tingting,ZHENG Rongshou,ZENG Hongmei,et al.Epidemiology of stomach cancer in China[J].Chin J Clin Oncol,2017,44(1):52-58.In Chinese with English abstract.
2. ZHAO Pengfei,CAO Bangwei.Apatinib for the treatment of gastric cancer[J].J Clin Pathol Res,2016,36(6):815-823.In Chinese with English abstract.
3. FENG Jiuhuan,QIN Shukui,WANG Lin.Clinical and experimental progress of mesylate apatinib[J].Chin Clin Oncol,2017,22(4):345-356.In Chinese with English abstract.
4. BAO Mingliang,YANG Runxiang,GAO Chunlin,et al.Efficacy of apatinib second-line treatment of advanced gastric cancer[J].Home Med,2016,(9):24-25.In Chinese with English abstract.
5. XIAO Bin.Clinical curative effect of apatinib mesylate combined with chemotherapy for treatment of advanced gastric cancer[J].China Health Care Nutr,2016,26(21):30.In Chinese with English abstract.
6. DING Lu,XIA Yunhong,WANG Weimin,et al.Efficacy and prognosis of apatinib mesylate and tegafur in the treatment of advanced gastric cancer[J].J Anhui Health Vocational Tech Coll,2017,16(2):48-49,133.In Chinese.
7. DUAN Hongrui,SONG Yan,JIANG Xiaoyan.Efficacy of apatinib combined with FOLFOX chemotherapy in treatment of advanced gastric cancer[J].China Pract Med,2017,12(28):155-157.In Chinese.
8. CHEN Mi.Clinical research of apatinib combined with thermal therapy in advanced gastric cancer with malignant ascites[J].Med Front,2016,6(36):123-125.In Chinese with English abstract.
9. JING Xiaohui.Effect of apatinib combined with tegafur as first-line therapy on elderly patients with advanced gastric cancer[J].Chin J Pract Med,2016,43(10):37-39.In Chinese with English abstract.
10. GAO Jinping,HAN Tao,PIAO Ying,et al.Apatinib combined with tegafur in treatment of elderly or emaciated patients with advanced gastric cancer[J].Clin J Med Offic,2017,45(1):9-12.In Chinese with English abstract.
11. HU Shanshan,XIANG Mei,LU Ping,et al.Clinical efficacy of apatinib combined with tegafur as first-line therapy on elderly patients with advanced gastric cancer[J].Health Care Guide,2016,(36):33.In Chinese.
12. ZHAN Zhixiang.Short-term efficacy and prognosis analysis of apatinib combined with irinotecan and 5-FU on patients with advanced gastric cancer[J].Chin J Pract Med,2017,44(13):39-42.In Chinese with English abstract.
13. WEN Feng,XIANG Yan,WANG Lei.Clinical study of apatinib tablets in the treatment of advanced gastric cancer[J].Chin J Clin Pharmacol,2017,33(7):589-591.In Chinese with English abstract.
14. WU Zhiwei,CAI Jun,LU Wangkun,et al.Clinical study of apatinib combined with tegafur as second line treatment for advanced gastric cancer[J].China Mod Med,2017,24(23):69-71,75.In Chinese with English abstract.
15. LI Qian.Clinical effect of apatinib in the treatment of chemotherapy-resistant advanced gastric cancer[J].J Imag Res Med Appl,2017,1(4):226-227.In Chinese.
16. YANG Yanfeng,DONG Xuewei.Clinical efficacy of apatinib for advanced gastric cancer and prognostic influential factors[J].Pract J Cancer,2017,32(8):1318-1320.In Chinese with English abstract.
17. XUE Dan,CUI Lingzhi.Effect of apatinib on second-line chemotherapy refractory patients with advanced gastric cancer[J].Contemp Med Symposium,2016,14(22):126-127.In Chinese.
18. CHEN Zhiyong,ZHENG Qiuxiang,GUO Baoling.Comparisons of apatinib and tegafur as second-line treatment for advanced gastric cancer[J].Chin J Clin Ration Drug Use,2017,10(16):79-80.In Chinese.
19. ZHENG Guang,HAN Tingting,LU Xianghui.Clinical study on second-line treatment of advanced gastric cancer with apatinib and tegafur[J].China Health Care Nutr,2016,26(27):274.In Chinese.
20. WANG Pengyuan,SHANG Nana,LIU Zhi,et al.Clinical study on second-line treatment of advanced gastric cancer with apatinib and tegafur[J].J Taishan Med Coll,2016,37(8):919-920.In Chinese.
21. LI Jin,QIN Shukui,XU Jianming,et al.Apatinib for chemotherapy-refractory advanced metastatic gastric cancer:results from a randomized,placebo-controlled,parallel-arm,phase Ⅱ trial[J].J Clin Oncol,2013,31(26):3219-3225.
22. LI Jin,QIN Shukui,XU Jianming,et al.Randomized,double-blind,placebo-controlled phase Ⅲ trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J].J Clin Oncol,2016,34(13):1448-1454.
23. WANG Dapeng,SONG Shasha,WANG Kai.Clinical efficacy of apatinib mesylate combined with chemotherapy in treatment of advanced gastric cancer[J].World Latest Med Inf(Elect Vers),2016,16(87):130-131.In Chinese.
24. Expert Committee of Anti-tumor Safety Management,Chinese Society of Clinical Oncology,QIN Shukui,LI Jin.Expert consensus on treatment of gastric cancer with apatinib[J].Chin Clin Oncol,2015,20(9):841-847.In Chinese.
25. YU Zijun,HOU Helei,ZHANG Xiaochun.Progress in gastric cancer therapy through targeting VEGF/VEGFR pathway[J].Chin Clin Oncol,2016,21(6):564-568.In Chinese with English abstract.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口